Hebrew Anti-Cancer Number One, Composition for Treatment of Malignant Tumor
Anti-Cancer Number One, Composition for Treatment of Malignant Tumor Chinese medicine, Anti-Cancer Number One (ACNO) is new anti-neoplastic drug developed from Traditional Chinese Medicine. It has been used for 30 years in China and more than 20 years in Israel. Thousands of cancer patients were treated with ACNO. The efficacy of ACNO was 69.7% and ACNO combined with western medicine (electrochemical therapy) group was 84.3%.
The clinical results showed that ACNO can improve immune system, inhibit cancer cells, improve blood circulation to suppress the growth and metastasis of tumor, increase the sensitivity to other therapies, diminish toxic and adverse effects of other therapies and drugs, improve sleep, increase appetite, alleviate pain and stress, improve liver and kidney function, and prevent leukopenia caused by radiotherapy and chemotherapy.
It also elevates the body's anti-tumor capacity to reduce the relapse and metastasis and improve patient quality of life. The animal research was made in Tel-Aviv University of Israel. The results showed that ACNO increased natural killer cells activity and inhibited metastasis of tumor. (Ref.: International Immunopharmacology, 2001, 1:1947-1956) and kill the tumor cells 82.5% in vitro.
Ping Chuang Chong Ji, composition for treatment of bronchial asthma
Chinese Medicine, Ping Chuang Chong JI was made by tonic and anti-asthma Chinese herbs, It has been used for 30 years in China and almost 20 years in Israel, Thousands of patients were treated. The effective rate is 90%. The drug can improve pulmonary function, blood partial pressure and increase CD2, CD4, CD4/CD8, and reduce IgE in blood.
It also increases CAMP and suppresses CGMP to stable mast cells and inhibit it to release histamine etc. The drug protects lung cells and increases alveolar number and returns lung volume to normal, which were observed through electronic microscope.
Now, we finished the clinic research to treat asthma patients with Ping Chuan Chong Ji in the Pulmonary Institute of Chaim Sheba Medical Center, Tel-Hashomer Hospital, and the results will be published.